Scientists have identified genetic variants that help explain why weight-loss drugs such as Wegovy and Mounjaro work significantly more effectively for some people than others, according to a study in the journal Nature. A examination involving 15,000 people taking these medications found that those carrying specific gene variations lost significantly more weight over roughly around eight months of treatment. Whilst participants lost approximately 11.7 per cent of their body weight, some shed as much as 30 per cent whilst others saw little change. The findings could also help explain why certain individuals encounter serious side-effects including nausea and vomiting. Experts suggest the genetic factors, though modest in their influence, work alongside other elements such as age, sex and ethnic background to shape how successfully these widely-used obesity treatments perform.
The genetic finding changing obesity management
Researchers analysing data from 23andMe discovered two key genetic variants that substantially affect how well weight-loss medications work. The first variant, associated with appetite regulation and digestion, is associated with greater weight loss when taking drugs like Wegovy and Mounjaro. People carrying a single copy of this variant lose approximately 0.76 kilogrammes on average more, whilst those with two copies can double that additional weight loss. The variant is especially prevalent among people of European ancestry, with 64 per cent carrying one copy and 16 per cent carrying two, compared to just 7 per cent of African Americans.
The second genetic variant identified in the study is linked to severe GI side-effects when using tirzepatide, the key component in Mounjaro. Researchers found that roughly 1 per cent of people carrying this variant develop extremely intense vomiting—nearly 15 times more severe than typical side-effects. Professor Ruth Loos from the University of Copenhagen, who commented on the research, emphasised that whilst the genetic effects are fairly modest, they are comparable to other influential factors and should not be overlooked as insignificant in determining individual drug responses.
- Genetic variants impact weight loss by around 0.76 kilogrammes per person
- European ancestry populations display greater frequency of weight-loss associated genes
- Second genetic variant elevates risk of severe nausea and vomiting
- Genetic factors function together with age, sex and ethnicity in determining effectiveness
How genetic factors affect medication effectiveness
The weight-loss approach outlined
The main genetic variant identified in the research affects the body’s appetite management and digestion, significantly impacting how weight-loss medications perform. Individuals with this variant demonstrate improved weight loss when taking drugs such as Wegovy and Mounjaro, with studies indicating an extra 0.76 kilogrammes reduced on average relative to those without the variant. The mechanism is linked to how the genes engage with the medications’ appetite-suppressing effects, amplifying their effectiveness in suppressing hunger and promoting satiety throughout treatment.
The impact becomes even more marked for those possessing two copies of the genetic variant. These persons can effectively increase their additional weight loss, possibly achieving significant advantages over those with one copy when undertaking obesity treatment. This genetic doubling effect constitutes a substantial difference in outcomes, especially important for individuals seeking greatest clinical advantage. However, researchers emphasise that this genetic advantage comes at a cost, as those affected also suffer heightened gastrointestinal side-effects, including nausea and vomiting in the course of treatment.
Heritage and genetic variation
The prevalence of this weight-loss-related genetic variant shows considerable variation across different populations, with ancestry being instrumental in likelihood of inheritance. European ancestry populations show substantially elevated carrier rates relative to other ethnic groups, demonstrating genetic diversity across global populations. This disparity carries significant implications for personalised medicine approaches and understanding why weight-loss drug effectiveness may be different across individuals from different ethnic backgrounds, potentially influencing treatment planning and outcome expectations.
| Population Group | Percentage Carrying Gene Variant |
|---|---|
| European ancestry (one copy) | 64% |
| European ancestry (two copies) | 16% |
| African American (one copy) | 7% |
| African American (two copies) | Data not specified |
Understanding these genetic distributions helps explain observed differences in medication response across different populations. The notably elevated occurrence of the weight-reduction variant among people of European descent suggests they may experience greater advantages from these drugs on average. Conversely, reduced carrier frequencies in African American populations indicate distinct genetic patterns that may necessitate different treatment approaches or modified expectations regarding weight-reduction results with current obesity medications.
Beyond hereditary factors: the broader context
Whilst inherited differences provide valuable insights into individual drug responses, researchers emphasise that inherited factors represent only one component of a considerably larger puzzle. Professor Ruth Loos observes that the genetic effect, though modest, stays “similar to other factors – and not trivial.” This indicates that many other variables influence how successfully weight-loss medications work for each person. Sex, years, daily habits, metabolic rate and general health condition all play a significant role to results from treatment, sometimes outweighing genetic predisposition entirely.
The complexity of personalized medical treatment is highlighted when examining how 15,000 trial participants experienced widely varying weight loss despite taking identical medications. Some lost 30 percent of their total weight over eight months, whilst others saw little change. This striking difference underscores that genetic factors by themselves cannot predict success. External conditions, compliance with treatment regimens, eating patterns and personal metabolic characteristics operate in concert with genetic blueprints to determine final results, pointing to the need for a nuanced approach to weight management remains vital.
- Sex differences may impact drug metabolism and weight loss outcomes considerably
- Age influences metabolic rate and drug efficacy in observable fashion
- Ethnic background determines both genetics and environmental health influences
- Lifestyle choices and dietary habits prove vital despite genetic predisposition
- Individual health conditions affect medication responses unpredictably
Sex, age and ethnicity variables
Sex differences have a significant impact in influencing how weight-loss medications affect individuals, with recent studies suggesting men and women might have varying responses to drugs like Wegovy and Mounjaro. Hormonal differences, differences in body composition and different metabolic rates between sexes could impact drug uptake and efficacy. Age likewise affects treatment success, as older people generally experience slower metabolic rates and might encounter different medication processing compared to younger people, potentially affecting weight loss outcomes and side-effect intensity.
Ethnicity includes both genetic and socioeconomic dimensions that shape medication outcomes beyond simple genetic inheritance. Dietary customs across cultures, healthcare availability, the affordability of medications and lifestyle choices vary significantly across ethnic groups, all impacting how well weight-loss medications work. Researchers accept that comprehending these overlapping factors demands thorough examination beyond genetic investigation by itself, making certain that future treatment guidelines address the needs of diverse populations equitably and efficiently.
From lab results to clinical practice
The identification of genetic variants affecting weight-management medication effectiveness opens promising avenues for personalised medicine in weight management. Translating these research results into clinical practice demands thoughtful evaluation of how genetic screening could be incorporated within NHS prescription guidelines and private healthcare services. Healthcare professionals may eventually use genetic screening to determine which patients will respond most favourably to particular drugs, potentially enhancing clinical results and reducing unnecessary side-effects. However, implementing such testing across the system presents operational and budgetary obstacles that the health service must tackle systematically.
Current obesity treatment continues to be largely one-size-fits-all, with patients receiving identical medications irrespective of their genetic makeup. As genetic understanding advances, clinicians could tailor prescriptions to individual genetic profiles, optimising weight reduction whilst minimising adverse reactions. This shift towards precision medicine requires funding in genetic testing infrastructure, healthcare worker training and revised treatment protocols. The research indicates that whilst genetic factors contribute modestly, their identification combined with assessment of other variables could significantly enhance treatment efficacy and patient satisfaction across diverse populations.
The precision medicine opportunity
Precision medicine marks a significant departure from conventional treatment guidelines towards individualised healthcare strategies based on genetic and phenotypic characteristics. By establishing which individuals have beneficial genetic variants, clinicians could improve drug choice and dosage schedules, thereby enhancing weight loss outcomes whilst reducing nausea and vomiting side effects. This approach offers more efficient resource use, improved patient experiences and greater assurance in obesity management across the NHS and private healthcare providers.
- Genetic screening can predict individual drug response patterns precisely
- Personalised dosing regimens could reduce negative reactions considerably
- Precision approaches optimise treatment satisfaction and patient outcomes markedly
What this signifies for patients today
For the many people presently using weight-loss medications like Wegovy and Mounjaro, these hereditary insights offer valuable understanding into why their experiences differ so dramatically. Whilst hereditary elements represent only a limited effect on drug effectiveness, they work together with other major factors including sex, age and racial heritage to shape individual outcomes. Understanding these trends helps clarify why some patients see substantial weight losses of 30 per cent or more, whilst others see little benefit despite taking the same drugs. This knowledge supports the disappointment patients widely experience when treatments fall short of expected benefits, suggesting biological factors rather than individual shortcoming play a crucial role.
At present, the NHS and independent healthcare providers dispense weight-loss drugs in the absence of genetic testing, which means patients are given uniform care irrespective of their individual genetic profile. Most people taking these drugs are often unaware whether they carry genetic variants that could predict their reaction or susceptibility to side-effects like intense nausea. Whilst genetic testing is not currently routinely available through the NHS, this research offers a foundation for future bespoke treatment methods. Patients discussing treatment options with medical professionals can now recognise that their genetic profile may influence outcomes, potentially encouraging more informed conversations about realistic expectations and individual risk factors before beginning medication.